{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T12:15:35Z","timestamp":1788524135479,"version":"build-2803163510"},"reference-count":114,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,2,1]],"date-time":"2027-02-01T00:00:00Z","timestamp":1801440000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T00:00:00Z","timestamp":1787788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2027,2]]},"DOI":"10.1016\/j.imlet.2026.107236","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T06:52:27Z","timestamp":1787640747000},"page":"107236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Beyond the M-spike - immunoparesis and multiple myeloma. A narrative review"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6360-3488","authenticated-orcid":false,"given":"Elizabeth Sarah","family":"Mayne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0710-4828","authenticated-orcid":false,"given":"Catherine Mary","family":"Worsley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8761-2162","authenticated-orcid":false,"given":"Tracey Monica","family":"Wiggill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2026.107236_bib0001","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/10428194.2020.1855345","article-title":"Deep and partial immunoparesis is a poor prognostic factor for newly diagnosed multiple myeloma patients","volume":"62","author":"Geng","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.imlet.2026.107236_bib0002","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.21037\/tcr-21-1627","article-title":"Partial immunoparesis contributes to risk of early infections in patients with multiple myeloma","volume":"10","author":"Huang","year":"2021","journal-title":"Transl. Cancer Res."},{"key":"10.1016\/j.imlet.2026.107236_bib0003","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1182\/blood.2025028587","article-title":"A T-cell-based metric of immune age predicts outcomes in older patients with myeloma receiving daratumumab-based therapy","volume":"146","author":"Bruins","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0004","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1038\/leu.2014.110","article-title":"Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myeloma","volume":"28","author":"Kastritis","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2026.107236_bib0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188988","article-title":"Immunoparesis in newly diagnosed multiple myeloma patients: effects on overall survival and progression free survival in the Danish population","volume":"12","author":"Sorrig","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2026.107236_bib0006","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1038\/s41375-018-0163-4","article-title":"Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials","volume":"32","author":"Heaney","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2026.107236_bib0007","first-page":"14","article-title":"Clinical considerations for immunoparesis in multiple myeloma","author":"Chahin","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.imlet.2026.107236_bib0008","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1515\/cclm-2016-0748","article-title":"Immunoparesis in IgM gammopathies as a useful biomarker to predict disease progression","volume":"55","author":"Andrade-Campos","year":"2017","journal-title":"Clin. Chem. Lab. Med."},{"issue":"Suppl 2","key":"10.1016\/j.imlet.2026.107236_bib0009","first-page":"S4","article-title":"The immune system in multiple myeloma and precursor states: lessons and implications for immunotherapy and interception","volume":"98","author":"Dhodapkar","year":"2023","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0010","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.hoc.2023.12.011","article-title":"Immune-pathogenesis of myeloma","volume":"38","author":"Dhodapkar","year":"2024","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.imlet.2026.107236_bib0011","series-title":"World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.imlet.2026.107236_bib0012","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Multiple myeloma: 2022 update on diagnosis, risk stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0013","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1002\/ajh.23355","article-title":"Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age","volume":"88","author":"Cherry","year":"2013","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0014","first-page":"9","article-title":"Dissecting molecular mechanisms of immune microenvironment dysfunction in multiple myeloma and precursor conditions","author":"Moscvin","year":"2023","journal-title":"J. Cancer Metastasis Treat."},{"key":"10.1016\/j.imlet.2026.107236_bib0015","first-page":"16","article-title":"Invasive pneumococcal disease unmasks monoclonal immunoglobulins and antibody deficiencies: a multicenter prospective study in adults","author":"H\u00e4rnqvist","year":"2026","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2026.107236_bib0016","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1056\/NEJMra2412716","article-title":"Monoclonal gammopathy of undetermined significance","volume":"393","author":"Rajkumar","year":"2025","journal-title":"New Eng. J. Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0017","doi-asserted-by":"crossref","first-page":"449","DOI":"10.7326\/M23-2540","article-title":"Development of a multivariable model to predict the need for bone marrow sampling in persons with monoclonal gammopathy of undetermined significance: a cohort study nested in a clinical trial","volume":"177","author":"Eythorsson","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.632564","article-title":"Co-evolution of immune response in multiple myeloma: implications for immune prevention","volume":"12","author":"Mccachren","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0019","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1182\/blood-2013-05-505487","article-title":"Monoclonal gammopathy of undetermined significance and risk of lymphoid and myeloid malignancies: 728 cases followed up to 30 years in Sweden","volume":"123","author":"Turesson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0020","doi-asserted-by":"crossref","first-page":"854","DOI":"10.3324\/haematol.2011.054015","article-title":"Monoclonal gammopathy of undetermined significance and risk of infections: a population-based study","volume":"97","author":"Kristinsson","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2026.107236_bib0021","doi-asserted-by":"crossref","first-page":"2997","DOI":"10.1038\/s41375-025-02762-9","article-title":"Increased risk of infections in smoldering multiple myeloma: results from the screened iStopMM study","volume":"39","author":"Andersen","year":"2025","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2026.107236_bib0022","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1080\/10428194.2018.1543883","article-title":"Is complement C1q a potential marker for tumor burden and immunodeficiency in multiple myeloma?","volume":"60","author":"Yang","year":"2019","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.imlet.2026.107236_bib0023","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.3389\/fimmu.2020.01292","article-title":"Globular C1q receptor (gC1qR\/p32\/HABP1) suppresses the tumor-inhibiting role of C1q and promotes tumor proliferation in 1q21-amplified multiple myeloma","volume":"11","author":"Xu","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0024","first-page":"240","article-title":"Dynamic changes in serum complements during chemotherapy in patients with multiple myeloma and their correlations with disease markers","volume":"189","author":"Nagumantry","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0025","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s10238-025-01561-x","article-title":"Decreased STING predicts adverse efficacy in bortezomib regimens and poor survival in multiple myeloma","volume":"25","author":"Liu","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0026","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1182\/blood.2019004537","article-title":"Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma","volume":"136","author":"Perez","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0027","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1038\/s41598-024-52922-7","article-title":"A neutrophil extracellular trap-related risk score predicts prognosis and characterizes the tumor microenvironment in multiple myeloma","volume":"14","author":"Zhao","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2026.107236_bib0028","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/ejh.14200","article-title":"Decreased neutrophil function in newly diagnosed multiple myeloma patients is restored with lenalidomide therapy","volume":"113","author":"Askman","year":"2024","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0029","article-title":"Distinct phenotype of neutrophil, monocyte, and eosinophil populations indicates altered myelopoiesis in a subset of patients with multiple myeloma","volume":"12","author":"Ong","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0030","first-page":"9","article-title":"Lenalidomide and pomalidomide improve function and induce Fc\u03b3RI\/CD64 in multiple myeloma neutrophils","author":"Romano","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.imlet.2026.107236_bib0031","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1038\/s41598-020-58859-x","article-title":"High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling","volume":"10","author":"Romano","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.imlet.2026.107236_bib0032","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/6344344","article-title":"Bone marrow neutrophils of multiple myeloma patients exhibit myeloid-derived suppressor cell activity","volume":"2021","author":"Petersson","year":"2021","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.imlet.2026.107236_bib0033","doi-asserted-by":"crossref","DOI":"10.1016\/j.exphem.2018.06.288","article-title":"Bone marrow eosinophils in plasma cell disorders","volume":"66","author":"Wichert","year":"2018","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0034","article-title":"Induction of malignant plasma cell proliferation by eosinophils","volume":"8","author":"Wong","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2026.107236_bib0035","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s40164-024-00578-4","article-title":"Natural killer cell biology and therapy in multiple myeloma: challenges and opportunities","volume":"13","author":"Bisht","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0036","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.3324\/haematol.2020.277525","article-title":"Myeloma natural killer cells are exhausted and have impaired regulation of activation","volume":"106","author":"D'souza","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2026.107236_bib0037","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/imm.12082","article-title":"Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy","volume":"139","author":"Costello","year":"2013","journal-title":"Immunology"},{"key":"10.1016\/j.imlet.2026.107236_bib0038","doi-asserted-by":"crossref","first-page":"8112","DOI":"10.3390\/ijms21218112","article-title":"Assessment of NK cell activity based on NK cell-specific receptor synergy in peripheral blood mononuclear cells and whole blood","volume":"21","author":"Kim","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.imlet.2026.107236_bib0039","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2147\/ITT.S534784","article-title":"T cells dysfunction in multiple myeloma","volume":"14","author":"Cai","year":"2025","journal-title":"Immunotargets Ther."},{"key":"10.1016\/j.imlet.2026.107236_bib0040","doi-asserted-by":"crossref","first-page":"17958","DOI":"10.18632\/oncotarget.4641","article-title":"Elevated Th22 as well as Th17 cells associated with therapeutic outcome and clinical stage are potential targets in patients with multiple myeloma","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.imlet.2026.107236_bib0041","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1200\/JCO.19.01740","article-title":"Randomized trial of lenalidomide versus observation in smoldering multiple myeloma","volume":"38","author":"Lonial","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0042","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1182\/blood-2015-10-662320","article-title":"Immune status of high-risk smoldering multiple myeloma patients and its therapeutic modulation under LenDex: a longitudinal analysis","volume":"127","author":"Paiva","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0043","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1182\/blood-2008-03-143222","article-title":"Dendritic cells mediate the induction of polyfunctional human IL17-producing cells (Th17-1 cells) enriched in the bone marrow of patients with myeloma","volume":"112","author":"Dhodapkar","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0044","doi-asserted-by":"crossref","first-page":"5385","DOI":"10.1182\/blood-2009-10-246660","article-title":"Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma","volume":"115","author":"Prabhala","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0045","doi-asserted-by":"crossref","first-page":"920","DOI":"10.3109\/10428191003699563","article-title":"Dysregulation in T helper 1\/T helper 2 cytokine ratios in patients with multiple myeloma","volume":"51","author":"Sharma","year":"2010","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.imlet.2026.107236_bib0046","doi-asserted-by":"crossref","first-page":"3554","DOI":"10.1182\/blood-2010-05-283895","article-title":"A novel role of IL-17-producing lymphocytes in mediating lytic bone disease in multiple myeloma","volume":"116","author":"Noonan","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0047","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1158\/1078-0432.CCR-19-1714","article-title":"Marrow-infiltrating regulatory T cells correlate with the presence of dysfunctional CD4(+)PD-1(+) cells and inferior survival in patients with newly diagnosed multiple myeloma","volume":"26","author":"Alrasheed","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imlet.2026.107236_bib0048","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1007\/s00262-014-1589-9","article-title":"FOXP3 and CTLA4 overexpression in multiple myeloma bone marrow as a sign of accumulation of CD4(+) T regulatory cells","volume":"63","author":"Braga","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.imlet.2026.107236_bib0049","doi-asserted-by":"crossref","first-page":"4290","DOI":"10.1158\/1078-0432.CCR-16-3192","article-title":"Targeting CD38 suppresses induction and function of T regulatory cells to mitigate immunosuppression in multiple myeloma","volume":"23","author":"Feng","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imlet.2026.107236_bib0050","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1111\/j.1365-2141.2008.07530.x","article-title":"CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) double negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden","volume":"144","author":"Feyler","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0051","article-title":"Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma","volume":"7","author":"Muthu Raja","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.imlet.2026.107236_bib0052","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1077768","article-title":"Aberrant metabolic processes promote the immunosuppressive microenvironment in multiple myeloma","volume":"13","author":"Lv","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0053","first-page":"5","article-title":"Early alterations in stem-like\/resident T cells, innate and myeloid cells in the bone marrow in preneoplastic gammopathy","author":"Bailur","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.imlet.2026.107236_bib0054","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1182\/blood-2006-10-051482","article-title":"Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway","volume":"110","author":"Liu","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0055","first-page":"1","article-title":"The TCF1-Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness","author":"Wu","year":"2016","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0056","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/s41408-024-01172-x","article-title":"Multi-omics reveal immune microenvironment alterations in multiple myeloma and its precursor stages","volume":"14","author":"Cheng","year":"2024","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.imlet.2026.107236_bib0057","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1038\/s41467-020-15740-9","article-title":"Timing the initiation of multiple myeloma","volume":"11","author":"Rustad","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.imlet.2026.107236_bib0058","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.3389\/fimmu.2017.01347","article-title":"Pro-inflammatory state in monoclonal gammopathy of undetermined significance and in multiple myeloma is characterized by low sialylation of pathogen-specific and other monoclonal immunoglobulins","volume":"8","author":"Bosseboeuf","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0059","first-page":"2","article-title":"Monoclonal IgG in MGUS and multiple myeloma targets infectious pathogens","author":"Bosseboeuf","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.imlet.2026.107236_bib0060","first-page":"3","article-title":"Antigen-mediated regulation in monoclonal gammopathies and myeloma","author":"Nair","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.imlet.2026.107236_bib0061","doi-asserted-by":"crossref","first-page":"173ra23","DOI":"10.1126\/scitranslmed.3005407","article-title":"CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation","volume":"5","author":"Flores-Borja","year":"2013","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0062","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.immuni.2015.04.005","article-title":"Regulatory B cells: origin, phenotype, and function","volume":"42","author":"Rosser","year":"2015","journal-title":"Immunity"},{"key":"10.1016\/j.imlet.2026.107236_bib0063","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2017.24","article-title":"Regulatory B cell-myeloma cell interaction confers immunosuppression and promotes their survival in the bone marrow milieu","volume":"7","author":"Zhang","year":"2017","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.imlet.2026.107236_bib0064","first-page":"10","article-title":"Differential function of a novel population of the CD19+CD24hiCD38hi Bregs in psoriasis and multiple myeloma","author":"Bartosinska","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.imlet.2026.107236_bib0065","doi-asserted-by":"crossref","first-page":"3054","DOI":"10.1002\/cam4.5228","article-title":"A stratified therapeutic model incorporated with studies on regulatory B cells for elderly patients with newly diagnosed multiple myeloma","volume":"12","author":"Tang","year":"2023","journal-title":"Cancer Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0066","doi-asserted-by":"crossref","first-page":"9219","DOI":"10.1200\/JCO.2005.03.2086","article-title":"Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom medical research council trials between 1980 and 2002\u2013medical research council adult leukaemia working party","volume":"23","author":"Augustson","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0067","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0068","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S2352-3026(21)00283-0","article-title":"Consensus guidelines and recommendations for infection prevention in multiple myeloma: a report from the international myeloma working group","volume":"9","author":"Raje","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0069","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/ejh.13190","article-title":"Risk factors for infections in newly diagnosed multiple myeloma patients: a Danish retrospective nationwide cohort study","volume":"102","author":"S\u00f8rrig","year":"2019","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0070","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12879-016-2155-1","article-title":"Risk factors and characteristics of blood stream infections in patients with newly diagnosed multiple myeloma","volume":"17","author":"Huang","year":"2017","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107236_bib0071","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.clml.2024.04.002","article-title":"Burden of infection in patients with and without secondary immunodeficiency disease following diagnosis of a mature B cell malignancy","volume":"24","author":"Richter","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.imlet.2026.107236_bib0072","doi-asserted-by":"crossref","DOI":"10.1155\/ah\/5340241","article-title":"Multiple myeloma and secondary immunodeficiency: a retrospective database analysis assessing burden of infection and treatment patterns","volume":"2025","author":"Siffel","year":"2025","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0073","doi-asserted-by":"crossref","DOI":"10.12659\/MSM.930241","article-title":"Secondary immunodeficiency and hypogammaglobulinemia with IgG levels of <5 g\/L in patients with multiple myeloma: a retrospective study between 2012 and 2020 at a university hospital in China","volume":"27","author":"Ye","year":"2021","journal-title":"Med. Sci. Monit."},{"key":"10.1016\/j.imlet.2026.107236_bib0074","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1007\/s00277-019-03621-1","article-title":"The risk of infections in multiple myeloma before and after the advent of novel agents: a 12-year survey","volume":"98","author":"Brioli","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0075","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.htct.2019.02.005","article-title":"Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan","volume":"41","author":"Zahid","year":"2019","journal-title":"Hematol. Transfus. Cell Ther."},{"key":"10.1016\/j.imlet.2026.107236_bib0076","first-page":"163","article-title":"Risk of infections in multiple myeloma. A population based study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry","volume":"110","author":"Blimark","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2026.107236_bib0077","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14439","article-title":"Invasive fungal diseases in patients with multiple myeloma: experience at a large, urban referral center","volume":"27","author":"Baneman","year":"2025","journal-title":"Transpl. Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107236_bib0078","article-title":"Invasive fungal infections in patients with multiple myeloma: a possible growing problem in hematology and infectious diseases","volume":"11","author":"Valkovic","year":"2024","journal-title":"Ther. Adv. Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107236_bib0079","first-page":"179","article-title":"Respiratory syncytial virus and other vaccine-preventable infections in multiple myeloma. A population-based study on 8,672 myeloma patients diagnosed 2008-2021 from the Swedish myeloma registry","volume":"110","author":"Einarsdottir","year":"2025","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2026.107236_bib0080","first-page":"2425","article-title":"Community-acquired respiratory infections are common in patients with non-Hodgkin lymphoma and multiple myeloma","volume":"26","author":"Lavi","year":"2018","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.imlet.2026.107236_bib0081","article-title":"Outcomes and risk factors for influenza and respiratory syncytial virus lower respiratory tract infections and mortality in patients with lymphoma or multiple myeloma: a 7-year retrospective cohort study","volume":"12","author":"Shafat","year":"2025","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107236_bib0082","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3324\/haematol.2014.107714","article-title":"Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients","volume":"100","author":"Blimark","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.imlet.2026.107236_bib0083","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/ejh.13066","article-title":"Risk factors for blood stream infections in multiple myeloma: a population-based study of 1154 patients in Denmark","volume":"101","author":"S\u00f8rrig","year":"2018","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0084","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A predictive model for risk of early grade\u2009\u2265\u20093 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.imlet.2026.107236_bib0085","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41408-022-00652-2","article-title":"A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma","volume":"12","author":"Encinas","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.imlet.2026.107236_bib0086","article-title":"Eastern cooperative oncology group, beta2-microglobulin, hemoglobin, and lactate dehydrogenase can predict early grade >\/= 3 infection in patients with newly diagnosed multiple myeloma: a real-world multicenter study","volume":"14","author":"Lu","year":"2023","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.imlet.2026.107236_bib0087","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.clml.2023.05.008","article-title":"Recommendations for management of secondary antibody deficiency in multiple myeloma","volume":"23","author":"Giralt","year":"2023","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.imlet.2026.107236_bib0088","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.3389\/fimmu.2017.01247","article-title":"Predicting risk of infection in patients with newly diagnosed multiple myeloma: utility of immune profiling","volume":"8","author":"Teh","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0089","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.7150\/jca.24288","article-title":"Multiple myeloma index for risk of infection","volume":"9","author":"Valkovic","year":"2018","journal-title":"J. Cancer"},{"key":"10.1016\/j.imlet.2026.107236_bib0090","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2025.1546641","article-title":"Preventing pneumococcal infections in patients with hematological malignancies: a review of evidence and recommendations based on modified Delphi consensus","volume":"15","author":"Seth","year":"2025","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0091","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1182\/bloodadvances.2022008073","article-title":"Interventions to reduce infections in patients with hematological malignancies: a systematic review and meta-analysis","volume":"7","author":"Chai","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.imlet.2026.107236_bib0092","first-page":"12","article-title":"Immunogenicity and safety of the recombinant adjuvanted herpes zoster vaccine in patients with chronic lymphocytic leukemia and multiple myeloma","author":"Diamantopoulos","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.imlet.2026.107236_bib0093","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1007\/s00277-025-06367-1","article-title":"Immune responses after one versus two influenza A\/B vaccinations in patients with multiple myeloma","volume":"104","author":"Enssle","year":"2025","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0094","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1532947","article-title":"Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients","volume":"16","author":"Raimondi","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.clml.2025.02.006","article-title":"Antibody response to pneumococcal, influenza, and COVID-19 vaccination in patients with multiple myeloma","author":"Singh","year":"2025","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.imlet.2026.107236_bib0096","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ejh.70013","article-title":"Vaccination in multiple myeloma: challenges and strategies","volume":"115","author":"Martino","year":"2025","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0097","doi-asserted-by":"crossref","first-page":"3822","DOI":"10.1002\/cam4.2253","article-title":"Response to pneumococcal vaccination in multiple myeloma","volume":"8","author":"Renaud","year":"2019","journal-title":"Cancer Med."},{"key":"10.1016\/j.imlet.2026.107236_bib0098","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1016\/S1470-2045(19)30506-6","article-title":"Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial","volume":"20","author":"Drayson","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0099","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta23620","article-title":"Prophylactic levofloxacin to prevent infections in newly diagnosed symptomatic myeloma: the TEAMM RCT","volume":"23","author":"Drayson","year":"2019","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.imlet.2026.107236_bib0100","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/ejh.13374","article-title":"Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: systematic review and meta-analysis","volume":"104","author":"Mohyuddin","year":"2020","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.imlet.2026.107236_bib0101","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz252","article-title":"Impact of levofloxacin for the prophylaxis of bloodstream infection on the gut microbiome in patients with hematologic malignancy","volume":"6","author":"Ziegler","year":"2019","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.imlet.2026.107236_bib0102","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1038\/s41375-025-02586-7","article-title":"Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European conference on infections in leukemia (ECIL)","volume":"39","author":"Pagano","year":"2025","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1016\/j.imlet.2026.107236_bib0103","first-page":"21","article-title":"The use of intravenous immune globulin in multiple myeloma","volume":"97","author":"Chapel","year":"1994","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0104","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1080\/10428190902856824","article-title":"Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta-analysis","volume":"50","author":"Raanani","year":"2009","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.imlet.2026.107236_bib0105","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.imlet.2026.107236_bib0106","doi-asserted-by":"crossref","first-page":"10073","DOI":"10.1182\/blood-2022-163733","article-title":"Infections and severe hypogammaglobulinemia in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"140","author":"Lancman","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0107","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European myeloma network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.imlet.2026.107236_bib0108","doi-asserted-by":"crossref","first-page":"e470","DOI":"10.1016\/j.clml.2020.12.026","article-title":"Efficacy of intravenous immunoglobulin for preventing infections in patients with multiple myeloma","volume":"21","author":"Lancman","year":"2021","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"10.1016\/j.imlet.2026.107236_bib0109","article-title":"To substitute or not? A systematic review of immunoglobulin replacement therapy in multiple myeloma patients treated with bispecific antibodies","volume":"16","author":"Paulsen","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0110","unstructured":"NHS. 2025. Clinical commissioning policy for the use of therapeutic immunoglobulin (Ig) England (2025) [Online]. Available: https:\/\/www.england.nhs.uk\/wp-content\/uploads\/2021\/12\/ccp-for-the-use-of-therapeutic-immunoglobulin-england-2025.pdf [Accessed Accessed: 21 April 2026]."},{"key":"10.1016\/j.imlet.2026.107236_bib0111","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2020-140056","article-title":"Effect of intravenous immunoglobulin on infections in multiple myeloma (MM) patients receiving daratumumab","volume":"136","author":"Lancman","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.imlet.2026.107236_bib0112","doi-asserted-by":"crossref","DOI":"10.1017\/S026646232400028X","article-title":"A systematic review of the cost and cost-effectiveness of immunoglobulin treatment in patients with hematological malignancies","volume":"40","author":"Carrillo De Albornoz","year":"2024","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.imlet.2026.107236_bib0113","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jaci.2016.09.023","article-title":"Update on the use of immunoglobulin in human disease: a review of evidence","volume":"139","author":"Perez","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.imlet.2026.107236_bib0114","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/bjh.14514","article-title":"Guidelines for screening and management of late and long-term consequences of myeloma and its treatment","volume":"176","author":"Snowden","year":"2017","journal-title":"Br. J. Haematol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826001100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T11:39:19Z","timestamp":1788521959000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826001100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,2]]},"references-count":114,"alternative-id":["S0165247826001100"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107236","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2027,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Beyond the M-spike - immunoparesis and multiple myeloma. A narrative review","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107236","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107236"}}